Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Exclusion Criteria

• •1. Subjects whose parents/legal guardians are unwilling or unable to give written informed consent to participate in the study.
• •2. History of any meningococcal B vaccine administration.
• •3. Previous ascertained or suspected disease caused by N. meningitidis.
• •4. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis.
• •5. History of allergic reaction to any vaccine component.
• •6. Significant chronic infection.
• •7. Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition).
• •8. Known or suspected impairment/alteration of the immune system resulting from (for example) receipt of chronic immunosuppressive therapy or immunostimulants.
• •9. Participation in another clinical trial within 90 days prior to enrolment or planned for during study.
• •10. Family members and household members of research staff.
• •11. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.